Rubius Therapeutics, Inc (RUBY)

Etorro trading 970x250
Rubius Therapeutics, Inc (RUBY) Logo

About Rubius Therapeutics, Inc

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Address: 399 Binney Street, Cambridge, MA, United States, 02139

Rubius Therapeutics, Inc News and around…

Latest news about Rubius Therapeutics, Inc (RUBY) common stock and company :

Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021
01 Dec, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it will host a virtual investor and analyst event focused on the company’s RED PLATFORM® and preclinical pipeline in oncology and autoimmunity, in particular

Rubius Therapeutics Becomes Oversold (RUBY)
24 Nov, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Rubius Therapeutics to Participate in Evercore ISI 4th Annual HealthCONx Conference
23 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on No

Rubius Therapeutics Presents Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, at the Society for Immunotherapy of Cancer’s Annual Meeting
12 Nov, 2021 Yahoo! Finance

U.S. FDA Recently Cleared Investigational New Drug Application for RTX-224CAMBRIDGE Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the poster presentation of preclinical data for RTX-224, a broad immune costimulatory ago

Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
09 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will provide a corporate update at the Jefferies London Healthcare Conference via a virtual pr

Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
08 Nov, 2021 Yahoo! Finance

U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for RTX-224, Rubius’ Third Oncology CandidateClinical Results Expected by Year-End or First Quarter 2022 in Phase 1 Trials of Single-Agent RTX-240 in Advanced Solid Tumors and Relapsed/Refractory Acute Myeloid Leukemia (AML)Laurence “Larry” Turka, M.D., Promoted to Head of Research & Translational Medicine CAMBRIDGE Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stag

Earnings Scheduled For November 8, 2021
08 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 ...

Is a Surprise Coming for Rubius Therapeutics (RUBY) This Earnings Season?
05 Nov, 2021 Yahoo! Finance

Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Rubius Therapeutics to Announce Third Quarter 2021 Financial Results
28 Oct, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report third quarter financial results on Monday, November 8, 2021, after market close. The company will not be hosting a teleconference in conjunction w

Rubius Therapeutics is Now Oversold (RUBY)
27 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

How The Pieces Add Up: SMMV Headed For $43
20 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $43.03 per unit.

Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
13 Oct, 2021 Yahoo! Finance

Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.

Rubius Therapeutics Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
01 Oct, 2021 Yahoo! Finance

CAMBRIDGE Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data for RTX-224, a broad immune costimulatory agonist for the treatment of cancer, at the upcoming Society for Immunotherapy of Cancer

RUBY Crosses Below Key Moving Average Level
20 Sep, 2021 FinancialContent

In trading on Monday, shares of Rubius Therapeutics Inc (RUBY) crossed below their 200 day moving average of $19.24, changing hands as low as $19.19 per share. Rubius Therapeutics Inc shares are currently trading off about 7.5% on the day..

Analysts Anticipate 13% Gains Ahead For SMMV
16 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $42.73 per unit.

Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference and H.C. Wainwright 23rd Annual Global Investment Conference in September 2021
01 Sep, 2021 FinancialContent
Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
30 Aug, 2021 FinancialContent
Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
30 Aug, 2021 Yahoo! Finance

CAMBRIDGE Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Jim Jogerst as chief business officer. He will oversee business development strategy and execution, including strategic partnerships, collaborat

Rubius Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
09 Aug, 2021 FinancialContent
Earnings Scheduled For August 9, 2021
09 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 ...

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Should You Buy Rubius Therapeutics (RUBY) Ahead of Earnings?
06 Aug, 2021 Yahoo! Finance

Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer
29 Jul, 2021 FinancialContent
11 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean Capital
28 Jul, 2021 Yahoo! Finance

In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons’ Euclidean Capital. If you want to skip our detailed analysis of Simons’ history, investment philosophy, and hedge fund performance, go directly to the 5 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean […]

Rubius Therapeutics to Announce Second Quarter 2021 Financial Results
22 Jul, 2021 FinancialContent
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
15 Jul, 2021 FinancialContent

Preclinical Data Show RTX-240 Promotes T Cell and NK Cell Activity Demonstrating Efficacy and Improved Safety Compared with a 4-1BB Agonist Antibody

Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
23 Jun, 2021 FinancialContent
Investors Grab RUBY 13.2% Cheaper Than Its Secondary Stock Offering
16 Jun, 2021 FinancialContent

Looking back to 92 days ago, Rubius Therapeutics Inc (RUBY) priced a 6,896,552 share secondary stock offering at $29.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative
14 Jun, 2021 Yahoo! Finance

Flagship Pioneering, the bioplatform innovation company, announced today that Stephen Hahn, M.D. will help lead its Preemptive Medicine and Health Security initiative as Chief Medical Officer, and join Flagship's Senior Leadership Team, effective June 16, 2021. Dr. Hahn served as the U.S. Food and Drug Administration Commissioner from 2019–2021. Prior to joining the FDA, he was the Chief Medical Executive, The University of Texas MD Anderson Cancer Center.

The open-source Contributor Covenant is now managed by the Organization for Ethical Source
27 May, 2021 FinancialContent

Managing the technical side of open-source projects is often hard enough, but throw in the inevitable conflicts between contributors, who are often very passionate about their contributions, and things get even harder. One way to establish ground rules for open-source communities is the Contributor Covenant, created by Coraline Ada Ehmke back in 2014. Like so […]

Rubius Therapeutics, Inc (RUBY) is a NASDAQ Common Stock listed in , ,

970x250